Literature DB >> 10888223

Changes in ganglioside contents, plasma sialic acid and cAMP levels in experimental hepatoma in mice.

C Q Lu1, J Lu, B L Wang, Y Z Cui.   

Abstract

The present study was designed to assess whether changes in glycolipids and cyclic AMP contents might serve as markers for the diagnosis of malignancy in the liver. The experimental model was a transplantable murine hepatoma. Experimental mice were divided into three groups: (1) a therapeutic group, which had been transplanted with hepatoma and treated with the antimetabolism drug 5-fluorouracil (0.2 mg/day i.p.), (2) a control group, which had been transplanted with hepatoma and treated with 0.2 ml 0.9% NaCl/day and (3) a normal group of mice. The ganglioside and cAMP contents in the hepatoma tissue, plasma cAMP, total- and lipid-bound sialic acid levels and red blood cell membrane sialic acid levels were determined. Results showed that the ganglioside content, total and lipid-bound sialic acid levels in the control group were significantly higher than those in the livers of normal mice (p < 0.01) while these respective values in the therapeutic group were significantly lower than those in the control group (p < 0.01). The cAMP levels of tumor tissues and plasma in the control group were lower than those in normal mice. No significant difference in red blood cell membrane sialic acid content was observed between the therapeutic and control groups though levels for both were higher than those in normal mice. These results indicate that ganglioside content and sialic acid levels in hepatoma tissues were significantly elevated, and cAMP levels in hepatoma tissues were significantly decreased during proliferation and abnormal differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888223     DOI: 10.1023/a:1007029927664

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  21 in total

1.  Glycosphingolipid expression in solid tumours and transformed cell lines.

Authors:  B Berra; I Colombo; E Monteggia; G Montorfano; S Moretti; S Rapelli; E Sottocornola
Journal:  Indian J Biochem Biophys       Date:  1997 Feb-Apr       Impact factor: 1.918

2.  Influence of ganglioside GM3 and high density lipoprotein on the cohesion of mouse brain tumor cells.

Authors:  H Bai; T N Seyfried
Journal:  J Lipid Res       Date:  1997-01       Impact factor: 5.922

3.  Purification and characterization of a membrane-associated ganglioside sialidase from bovine brain.

Authors:  K Hata; T Wada; A Hasegawa; M Kiso; T Miyagi
Journal:  J Biochem       Date:  1998-05       Impact factor: 3.387

4.  Serum lipid-bound sialic acid as a marker in breast cancer.

Authors:  A M Dnistrian; M K Schwartz; N Katopodis; A A Fracchia; C C Stock
Journal:  Cancer       Date:  1982-11-01       Impact factor: 6.860

Review 5.  Cross-linking of cell surface ganglioside GM1 induces the selective apoptosis of mature CD8+ T lymphocytes.

Authors:  T O Nashar; N A Williams; T R Hirst; T O Nahar
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

6.  Ganglioside synthesis during the development of neuronal polarity. Major changes occur during axonogenesis and axon elongation, but not during dendrite growth or synaptogenesis.

Authors:  K Hirschberg; R Zisling; G van Echten-Deckert; A H Futerman
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

7.  Linkage-specific action of endogenous sialic acid O-acetyltransferase in Chinese hamster ovary cells.

Authors:  W X Shi; R Chammas; A Varki
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

Review 8.  Functional roles of gangliosides in bio-signaling.

Authors:  Y Nagai
Journal:  Behav Brain Res       Date:  1995-01-23       Impact factor: 3.332

9.  Inhibitory effects of milk gangliosides on the adhesion of Escherichia coli to human intestinal carcinoma cells.

Authors:  T Idota; H Kawakami
Journal:  Biosci Biotechnol Biochem       Date:  1995-01       Impact factor: 2.043

10.  Serum sialic acid in malignant tumors, bacterial infections, and chronic liver diseases.

Authors:  N Stefenelli; H Klotz; A Engel; P Bauer
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.